Each data point represents the average of triplicate wells; data analysis was carried out by nonlinear regression analysis with GraphPad Prism software. Each experiment was repeated twice.
Cell lines and culture conditions
The human melanoma cells M21 and M21-L were kindly provided by Dr. David Cheresh and
The Scripps Research Institute (La Jolla, CA, USA). Cells were grown in RPMI 1640
supplemented with 10% foetal bovine serum (FBS), 1% L-glutamine and 1%
Penicillin/Streptomycin in a humidified incubator at 37 °C and 5% CO2.
In vitro cytotoxicity assay
Cell viability was quantified by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells were plated at density of 3000 cells well −1 and incubated
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overnight to allow adherence. The following day, cells were treated with serial dilutions of each compound or 0.1% DMSO as control. After 2 h incubation, cells were centrifuged at 1200 rpm for 5 min, supernatant containing the compounds was removed and replaced with fresh medium. Cells were further incubated for 70 h as described above and at the end of treatment, 5 µL of MTT (5 mg mL −1 in deionized H2O, Sigma #M5655) were added to each well and cells incubated for another 2 hours. Finally, 100 µL of lysis buffer (10% SDS, 10 mM HCl) were added, and cells placed in the incubator overnight for the formazan crystal solubilization.
Absorbance at 540 nm was measured using FLUOstar Omega (BMG Labtech) instrument and the growth inhibition ratio was calculated. Blank controls detecting cell-free media absorbance were performed in parallel. Three experimental replicates were used. The half-maximal inhibitory concentration values (IC50) were obtained from viability curves by fitting data to the four-parameter logistic equation using GraphPad Prism 6. The cell viability was expressed as percentage relative to the respective control conditions (0.1% of DMSO).
Flow cytometry analysis
The M21 and M21-L cells were plated at density of 80000 cells mL 
II. Chemical synthesis

General information
All experiments requiring anhydrous conditions were performed using oven-dried glassware under argon atmosphere, unless otherwise stated. DCM was distilled from CaH2, THF was distilled from sodium/benzophenone, DMF was dried over 4Å molecular sieves. Chemicals and solvents (reagent-grade or analytical-grade) were purchased from commercial sources and used without further purification. Macherey-Nagel silica gel "Kieselgel 60" with 40 -63 µm 
NMR spectroscopy
Proton NMR-spectra were recorded on a spectrometer operating at 400.16 MHz. Carbon NMRspectra were recorded on a spectrometer operating at 100.63 MHz, with complete proton 
Scheme S2. Synthesis of cyclo[DKP-RGD]-PEG4-Val-Ala-PABC-Cry-55gly (10) and cyclo[DKP-isoDGR]-PEG4-Val-Ala-PABC-Cry-55gly (11
Synthetic procedures, characterization details Synthesis of cyclo[DKP-RGD]-PEG4-Val-Ala-PABC-Cry-55gly (10) and cyclo[DKPisoDGR]-PEG4-Val-Ala-PABC-Cry-55gly (11)
4-Pentynamido-Val-Ala-PABA (15)
Fmoc-Val-Ala-PABA 1 (300 mg, 0.58 mmol, 1 eq) was dissolved in dry DMF (6 mL), piperidine (300 µL) was added and the reaction was stirred at RT for 2 h. The solvents were removed, and the residue was used for the next step. 
4-Pentynamido-Val-Ala-PABC-Cry-55gly (9)
Cryptophycin-55 glycinate (7) was prepared as previously described.
2 7 (8.1 mg, 10.6 µmol, 1 eq) and 8 (6.3 mg, 11.7 µmol, 1.1 eq) were dissolved in anhydrous DMF (300 µL). DIPEA (5.4 µL, 31.8 µmol, 3 eq) was added and the mixture was stirred for 4 h at RT, followed by RP-HPLC purification to yield 9 as colorless solid (7.5 mg, 61%). and sodium ascorbate (0.19 mg, 0.95 µmol, 0.4 eq) were dissolved in DMF/H2O (1:1, 1 mL, S10 degassed) and stirred for 24 h at 35 °C, followed by RP-HPLC purification to yield 10 as colorless solid (2.9 mg, 60%). 4-Pentynoil-Cry-55gly (12) 7 (6 mg, 7.8 µmol, 1 eq), 4-pentynoic acid (3 mg, 31.5 µmol, 4 eq), PyBOP (16 mg, 31.5 µmol, 4 eq) and HOBt (5.5 mg, 35.5 µmol, 4.5 eq) were dissolved in anhydrous DMF (500 µL) under argon. DIPEA (6 µL, 35.5 µmol, 4.5 eq) was added and the mixture was stirred for 4 h at RT, followed by RP-HPLC purification to yield 12 as colorless solid (6.2 mg, 95%). and sodium ascorbate (0.24 mg, 1.2 µmol, 0.4 eq) were dissolved in DMF/H2O (1:1, 600 µL, degassed) and stirred for 24 h at 35 °C, followed by RP-HPLC purification to yield 13 as colorless solid (4.4 mg, 85%). 
LC-MS
